Japan Market Report for Uterine Fibroid Embolization Devices 2017 - MedCore

Japan Market Report for Uterine Fibroid Embolization Devices 2017 - MedCore

  • May 2017 •
  • 218 pages •
  • Report ID: 4895080 •
  • Format: PDF

Uterine fibroid embolization (UFE), also known as uterine artery embolization (UAE) is a radiology treatment for fibroids.

Fibroids, also known as myomas, are masses of muscle tissue and fiber located on the wall of the uterus that can cause heavy bleeding and pain. Fibroids depend on the uterine arteries for nourishment, and they take significant blood supply from these vessels. UFE restricts blood flow to fibroids, causing them to shrink significantly.

This procedure does not involve general anesthesia and is appropriate for women who want an alternative to a myomectomy, also known as fibroidectomy. It is a much less invasive way to treat fibroids than a hysterectomy, has a much shorter recovery time and leaves almost no scarring. The effects of UFE on fertility are being researched; some results suggest that fertility after UFE is comparable to fertility after myomectomy.

Description
General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions

In Japan, embolization procedures are projected to increase over the forecast period. In the field of gynecology, the embolization market covers polyvinyl alcohol (PVA) particles and microspheres as well as the percentage of procedures performed using gelatin sponge particles.

The momentum towards embolization procedures was in part triggered by the approval of microspheres to enter the Japan market in 2013. Specifically, Nippon Kayaku (authorized distributor for Merit Medical Systems, Inc.) received authorization for the distribution and marketing of Embosphere Microspheres and HepaSphere Microspheres in June 2013.

Embosphere Microspheres are particularly valuable as “the most clinically studied round embolic, [that] provide consistent and predictable results for effective embolization in the treatment of uterine fibroids, hypervascular tumors, and arteriovenous malformations.”

They are often referred to as the gold standard for UFE procedures.
The increase in procedure numbers is further fueling the growth in total unit sales. The market is comprised of microspheres and PVA particle sub-markets respectively. There is an overarching market shift towards microsphere particles both in Japan and globally. The volume of microspheres required per procedure is much higher than the volume of PVA particles required per procedure; 2.4 microspheres are used for every 1.4 PVA particles required per procedure. The shift towards microspheres has augmented unit sales, causing them to increase at an even faster rate than procedure numbers.


Scope
2013-2023